Short-Term Estradiol Replacement in Postmenopausal Women Selectively Mutes Somatostatin’s Dose-Dependent Inhibition of Fasting Growth Hormone Secretion1
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
How estradiol stimulates pulsatile GH secretion in the human is not well understood. Here, we test the clinical hypothesis that estradiol stimulates GH secretion, in part, by opposing somatostatin's inhibition of GH release. To this end, 13 estrogen-withdrawn postmenopausal women received placebo or 1 mg micronized estradiol-17beta orally, twice daily for 14 days, in a prospectively randomized, patient-blinded, within-subject cross-over design. For each intervention, the dose-dependent suppressive actions of somatostatin were evaluated by infusing 0 (saline), 3, 10, 30, 100, or 300 microg/1.73 m(2).h somatostatin-14 continuously, iv, for 3 h, on separate mornings, in the fasting state, 48 h apart. Blood was sampled at 10-min intervals for 2 h before, for 3 h concurrently with, and for 1 h after each infusion. Serum GH concentrations were quantitated in an ultrasensitive chemiluminescence-based assay (detection threshold, 0.005 microg/L). In the estrogen-deficient milieu, constant iv somatostatin infusions inhibited steady-state serum GH concentrations (valley mean during the last 60 min of the infusion interval) in a dose-dependent manner (P < 10(-4) interventional effect). Maximally effective doses of somatostatin reduced the latter by 89 +/- 6.1% (mean +/- SEM) below the subject-specific preinfusion baseline. Estrogen administration increased the serum estradiol concentration from 12 +/- 1 to 245 +/- 35 pg/mL [42 +/- 4 to 920 +/- 110 pmol/L] (P < 10(-4)); decreased serum concentrations of LH (P = 0.018), FSH (P < 10(-4)), and insulin-like growth factor-I (P = 0.003); and elevated the fasting (6-h mean) serum GH concentration from 0.41 +/- 0.07 to 0.87 +/- 0.27 (P = 0.011). Estradiol supplementation did not alter somatostatin's maximal suppression of GH by 89 +/- 4.7% (P < 10(-4) below subject-specific preinfusion baseline), thus signifying unchanging somatostatin efficacy. In contrast, estradiol replacement significantly elevated the half-maximally inhibitory dose of infused somatostatin by 13.5-fold, from 0.43 (0.38-0.48, 95% group statistical confidence intervals) (placebo) to 6.0 (5.2-7.0) (estradiol) microg/1.73 m(2)/h (P < 10(-4)), denoting muting of somatostatin's inhibitory potency. The latter inference was confirmed by a concomitant 4-fold decrease in the exponential steepness of the somatostatin inhibitory dose-response function; viz., mean 1.42 (1.49 to 1.33) (placebo) vs. 0.34 (0.62 to 0.26) (estradiol) slope units (P < 10(-4)). The foregoing effects were specific, because estrogen did not alter somatostatin's dose-dependent enhancement (P < 10(-4)) of the orderliness of GH release patterns, as quantitated via the approximate entropy regularity statistic. In summary, short-term replacement of estradiol to midfollicular phase levels in postmenopausal women selectively reduces the potency, but not the efficacy, of somatostatin's dose-dependent inhibition of GH release. Estrogen supplementation does not modify somatostatin's reciprocal enhancement of the quantifiable orderliness (approximate entropy) of the GH secretory process. Accordingly, we postulate that estradiol can facilitate pulsatile GH secretion, in part, by opposing the repressive actions of somatostatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Giustina, A., & Veldhuis, J. D. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0353 · Cited by 1,253
Self-citationEffects of Estrogen and Sex Difference on Secretion of Human Growth Hormone1
FRANTZ, A. G., & RABKIN, M. T. (1965) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-25-11-1470 · Cited by 467
van den Berg, G., Veldhuis, J. D., Frölich, M., & Roelfsema, F. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.7.8675561 · Cited by 293
Self-citationMauras, N., Rogol, A. D., & Veldhuis, J. D. (1990) · Pediatric Research · doi:10.1203/00006450-199012000-00018 · Cited by 127 · cited 2×
“Infusion sessions were prescheduled for days 8, 10, 12, and 14 of placebo or estrogen intervention, because oral estrogen supplementation stimulates GH secretion consistently within 5‐7 days ( 23 , 25).”
BackgroundSelf-citationThe role of sexual steroids in the modulation of growth hormone (GH) secretion in humans.
Devesa, J., Lois, N., Arce, V., Diaz, M. J., Lima, L., & Tresguerres, J. A. F. (1991) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(91)90179-9 · Cited by 98 · cited 4×
“The oral route of estrogen delivery is especially, but not solely, effective in stimulating GH secretion, because higherdose transdermal estradiol administration can do likewise ( 12 ).”
BackgroundInfluentialActions of estrogen on pulsatile, nyctohemeral, and entropic modes of growth hormone secretion
Shah, N., Evans, W. S., & Veldhuis, J. D. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1351 · Cited by 82
Self-citation
Cited by
Qu, X.-D., Gaw Gonzalo, I. T., Al Sayed, M. Y., Cohan, P., Christenson, P. D., Swerdloff, R. S., Kelly, D. F., & Wang, C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1450 · Cited by 103
“Estrogen is likely to modulate the inhibitory effect of l-arginine on hypothalamic somatostatin and potentiates the GHRH-induced GH secretion (39).”
BackgroundUnequal impact of short-term testosterone repletion on the somatotropic axis of young and older men.
Gentili, A., Mulligan, T., Godschalk, M., Clore, J., Patrie, J., Iranmanesh, A., & Veldhuis, J. D. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8222 · Cited by 98
“In this regard, fixed infusions of GHRP-2 or GHRH likewise drive greater irregularity (elevated GH ApEn) of 24-h serum GH concentration profiles (5, 41, 66, 67, 70).”
BackgroundInfluentialSelf-citationImpact of Estradiol Supplementation on Dual Peptidyl Drive of GH Secretion in Postmenopausal Women
Veldhuis, J. D., Evans, W. S., & Bowers, C. Y. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8251 · Cited by 36
Self-citationKok, P., Paulo, R. C., Cosma, M., Mielke, K. L., Miles, J. M., Bowers, C. Y., & Veldhuis, J. D. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0522 · Cited by 35
Self-citationSex-steroid control of the aging somatotropic axis
Veldhuis, J. D., Erickson, D., Iranmanesh, A., Miles, J. M., & Bowers, C. Y. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.07.006 · Cited by 30
Self-citation
Metadata
- Authors
- Bray, M. J., Vick, T. M., Shah, N., Anderson, S. M., Rice, L. W., Iranmanesh, A., Evans, W. S., & Veldhuis, J. D.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-07
- Volume
- 86
- Issue
- 7
- Pages
- 3143-3149
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2133036501
- Cited by
- 56
- References
- 6
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Short-Term Estradiol Replacement in Postmenopausal Women Selectively Mutes Somatostatin’s Dose-Dependent Inhibition of Fasting Growth Hormone Secretion1. https://app.cochat.ai/papers/10.1210/jcem.86.7.7647
- The paper
- Bray, M. J., Vick, T. M., Shah, N., Anderson, S. M., Rice, L. W., Iranmanesh, A., Evans, W. S., & Veldhuis, J. D. (2001). Short-Term Estradiol Replacement in Postmenopausal Women Selectively Mutes Somatostatin’s Dose-Dependent Inhibition of Fasting Growth Hormone Secretion1. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem.86.7.7647
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.